Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma
Abstract Toripalimab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1). It has recently been approved as an immune checkpoint inhibitor in second-line therapies in patients with unresectable or metastatic melanoma; however, it may be associated with various immune-related adv...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Adis, Springer Healthcare,
2020-05-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|